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Background and Objectives. In recent years pul-
monary mucormycosis has been reported in patients
with leukemia and lymphoma and bone marrow
transplant recipients. It carries an extremely poor
prognosis. We report our experience of clinical find-
ings, diagnostic procedures, treatment and outcome
of mucormycosis diagnosed in neutropenic patients
affected by hematologic neoplasms admitted to our
Department.
Design and Methods. From November 1987 to July
1999 we observed 13 patients with mucormycosis.
Their median age was 61 years (range 20-75), and
they were predominantly in the aplastic post-
chemotherapy period (12/13), affected by acute
myeloid leukemia (11 cases ) or non-Hodgkin’s lym-
phoma (2 cases). Six patients (all with leukemia)
were receiving induction–consolidation therapy, 7
had progressive hematologic disease. At the onset
of infection all patients were neutropenic (N
<0.5×109/L). No patients had diabetes mellitus. Two
patients had been receiving steroid therapy for 5
and 7 days.
Results. The lung was involved in all cases (13/13);
disseminated disease was present in 8/13 patients.
All cultures (blood, sputum, nasal swabs and bron-
choalveolar lavage) were negative. In 3 patients a
histologic diagnosis was made in vivo: in 1 patient by
percutaneous pulmonary biopsy, in 1 patient by pul-
monary lobectomy, and in the last patient by percu-
taneous pulmonary biopsy confirmed by excision of
a cerebellar abscess. In the remaining 10 cases
diagnosis was made post-mortem. Five patients were
not treated, 2 because of poor clinical condition and
3 because fungal infection was not suspected.
Amphotericin B (1 mg/kg/day) was given empiri-
cally to 6 patients and 2 responded to treatment.
The remaining 2 patients with neurologic symptoms
at the onset of infection were treated with liposomal
amphotericin, Ambisome, one with 3 and one with
5 mg/kg/day; of these two patients the first died in
4 days; the second , with both pulmonary and cere-
bellar localizations, was treated successfully with 5
mg/kg/day for 4 weeks and then with 3 mg/kg/day,
and excision of a brain abscess at neutrophil recov-
ery (total dose of Ambisome: 12,000 mg). The 3
surviving leukemic patients were able to complete
subsequent consolidation therapy using ampho-
tericin B or liposomal amphotericin as secondary
prophylaxis during aplasia.
Interpretation and Conclusions. Mucormycosis in neu-
tropenic hematologic patients is rarely suspected. In
our patients infection was often characterized by dis-
seminated disease and a rapidly fatal course; only
early aggressive amphotericin B (or Ambisome)
treatment together with neutrophil recovery appeared
to improve the outcome. Diagnosis is very important
for programming antifungal therapy and secondary
prophylaxis with amphotericin B, because Mucor is
usually resistant to itraconazole.
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Mucormycosis is the preferred name fordisease caused by fungi of the order ofMucorales in compromised hosts. There
are 14 families in this order, of which 4 have
been associated with human disease. Members
of Mucoraceae are widespread in nature. These
fungi are common in the soil and can also be
found on decomposing plant and animal mat-
ter. Large numbers of small sporangiospores are
released into the air; because they are ubiqui-
tous, the likelihood of infection following
inhalation, ingestion or inoculation depends on
the host’s resistance mechanisms rather than
on the number of infectious particles. The
increasing incidence of mucormycosis has been
attributed to several predisposing conditions
including diabetes, malnutrition, acidosis,
steroid therapy and severe neutropenia. In
recent years pulmonary mucormycosis has been
reported in patients with leukemia, and lym-
phoma and in bone marrow transplant recipi-
ents,1-3 with an extremely poor prognosis in all
of them.
Clinical presentation includes rhinocerebral
involvement, pulmonary disease, gastrointesti-
nal and cutaneous localizations, and dissemi-
nated infection.
We report our experience of mucormycosis
diagnosed in our Department between 1987
and 1999 in neutropenic patients affected by
hematologic neoplasms.
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Design and Methods
In our Department 75 cases of invasive fila-
mentous fungal infections were diagnosed
between 1987 and 1999; of these we identified
13 hematologic patients with mucormycosis, 10
males, 3 females, median age 61 years (range 20-
75), predominantly in the aplastic post-chemo-
therapy period, (12/13), affected by acute
myeloid leukemia (11 cases) or non-Hodgkin’s
lymphoma (2 cases). Six patients were receiving
induction-consolidation therapy, 7 patients had
progressive hematologic disease. At the onset of
infection all patients were neutropenic (neu-
trophils < 0.5×109/L). Median days of previous
neutropenia were 10, range 5-18. Median days of
previous antibiotic therapy (ceftazidime, ami-
kacin, vancomycin) were 5, range 4-15. No
patients had diabetes mellitus. Two patients had
been receiving steroid therapy (prednisone 25
mg/day) for 5 and 7 days.
Results
Incidence
Among 653 new cases of acute leukemia
observed in the same period, the approximate
incidence of Mucor in acute leukemia was 1.6%. 
Clinical characteristics
Fever was the first sign of infection; cough and
acute pleural pain were very frequent. All patients
had pneumonia with a radiologic picture similar
to that of aspergillosis. Disseminated disease,
defined as infection in 2 or more non-contiguous
organs, was found in 8/13 cases (nose, liver, kid-
neys, heart, esophagus: post-mortem findings) and
4 of them had cerebral invasion. Mild hemopty-
sis occurred in only 1 patient; none had rhino-
cerebral infection.
At the onset of pulmonary infection chest com-
puted tomography (CT) scan performed early in
7 patients was able to demonstrate infiltrates
with the halo sign in 5 patients, including  2
patients with a negative standard chest X-ray.
Diagnosis
A definitive diagnosis of Mucor was made in vivo
and at autopsy when biopsy specimens showed
irregularly shaped, broad, non-septate hyphae
with branches occurring at right-angles. The
hyphae were visualized in tissue sections stained
with periodic acid-Schiff reaction and Grocott-
Gomori methanamine-silver nitrate. In only 3
patients was it possible to obtain the diagnosis
in vivo and it was always histologic: in the first
case diagnosis was obtained by percutaneous
pulmonary biopsy, in the second by pulmonary
lobectomy and in the third by percutaneous pul-
monary biopsy confirmed by the excision of a
cerebellar abscess. Cultures were always nega-
tive. Bronchoalveolar lavage was performed in 4
cases and was negative. 
In 3 patients with progression of hematologic
malignancy, the diagnosis of infection was not
suspected, but disseminated fungal disease was
found at post-mortem examination.
Antifungal therapy and clinical outcome
Five patients were not treated, 2 because of
poor clinical condition and 3 because fungal
infection was not suspected; they died rapidly.
Antifungal therapy was given to 8 patients;  6 cas-
es were treated with amphotericin B (1 mg/kg/
day), and 2 cases with Ambisome. Of the first
6 patients,  2 patients with only pneumonia
responded to treatment and continued antimy-
cotic treatment with amphotericin B up to total
doses of 2,170 and 2,560 mg; 2 patients with dis-
seminated disease and cerebral invasion had
rapidly fatal outcomes in 2-4 days despite
prompt antifungal therapy administration; 2
patients with disseminated disease progressively
worsened and died in 1-2 weeks during ampho-
tericin B therapy. One patient who responded
underwent pulmonary lobectomy for hemopty-
sis; surgery permitted the histologic diagnosis.
Two patients with both pneumonia and neuro-
logic symptoms at the onset of infection were
treated with liposomal amphotericin, Ambi-
some, one with 3 mg and one with 5 mg/kg/day;
the first patient died in 4 days; the second, a 26-
year old, treated with 5 mg/kg/day for 4 weeks,
survived and when neutrophils and platelets
recovered he successfully underwent drainage of
a cerebellar abscess for hypertensive encepha-
lopathy. He then completed antifungal therapy
with Ambisome 3 mg/kg/day up to a total dose
of 12,000 mg. The 3 surviving leukemic patients
were able to complete the subsequent consoli-
dation chemotherapy using amphotericin B (0.8-
1 mg/kg/day) or Ambisome (2-3 mg/kg/day)
during aplasia. The patient with the cerebellar
abscess underwent autologous bone marrow
transplantation 5 months later with Ambisome
3 mg/kg as secondary prophylaxis, without
relapse of mycosis.
At follow-up 1 patient with pneumonia pre-
sented mucormycosis at leukemia relapse after 1
year, during prolonged aplasia subsequent to sal-
vage chemotherapy, in progression of hemato-
logic disease; the other 2 remaining patients have
not had fungal relapses after 128 and 15 months
of follow-up.
Year of diagnosis, main clinical characteristics,
therapy and outcome are summarized in Table 1.
Discussion
Filamentous fungal infections are increasing
in immunocompromised hosts, particularly in
those with hematologic diseases. In our hema-
tologic population 153 post-mortem examina-
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tions performed in the period 1989-1995
showed mycotic infections in 31%  of autopsies;4
Aspergillus was by far the commonest species
encountered (73%), Candida spp. accounted for
14% and Mucor for 13%.This rate is  similar to
that reported by Tonso et al.5 in a study per-
formed by 18 Italian hematologic departments,
in which the incidence of mucormycosis among
filamentous mycoses observed during the same
period was 12%.
In a review of 1,186 consecutive patients who
underwent bone marrow transplantation
between 1974 and 1989 at the University of Min-
nesota Hospital, mucormycosis accounted for
2% of non-Candida fungal infections.6 Recently,
Penalver et al.7 reported 4 cases of mucormycosis
(0.9%) diagnosed between 1984 and 1997
among 345 patients undergoing bone marrow
transplantation. The incidence of mucormycosis
can be underestimated because diagnosis of this
specific fungus is difficult and the clinical picture
is similar to that produced by Aspergillus.
There are 2 main clinical manifestations of
Mucor: rhinocerebral infection starting in the
nasal sinuses and spreading to the face, palate,
orbits and brain, and pulmonary infection with
possible multivisceral embolic dissemination,
with a high mortality.8 In our hematologic neu-
tropenic patients the course of Mucor disease was
very aggressive and disseminated disease was
present in 8/13 patients with the main localiza-
tion being the lung, but also with involvement of
the kidneys, liver, heart, brain, and esophagus.
Patients with pulmonary mucormycosis had a
clinical and radiologic picture similar to that of
invasive pulmonary aspergillosis and in 7
patients prompt chest CT scan appeared helpful
in diagnosing filamentous fungal infection; only
1 patient had hemoptysis and was treated by
surgery, which also defined the correct histolog-
ic diagnosis. In our experience cerebral localiza-
tions were always a consequence of embolic dis-
semination in patients with pulmonary disease,
as previously described.9
Establishing the diagnosis is the central issue
in the management of mucormycosis. In neu-
tropenic patients ante-mortem diagnosis is unusu-
al because blood cultures are invariably nega-
tive; in pulmonary disease sputum cultures are
seldom helpful and bronchial washings have
yielded hyphal forms only on rare occasions.
Berns et al.9 noted that a mucoraceous fungus
was recovered from only 1 of 1,440 consecutive
bronchial brushing specimens, but that 1
instance was an autopsy-proven case of
mucormycosis. We obtained diagnosis in vivo
only by invasive methods (biopsy or surgery)
(Table 1).
In hematologic patients the most important
good prognostic factor is the outcome of the
hematologic disease.3 The importance of revers-
ing underlying factors is evident in the experience
with mucormycosis in transplant recipients.10 In
the University of Minnesota Hospital study none
of 3 allotransplanted patients with Mucor was a
long-term survivor,6 probably because of immu-
nosuppression. Neutrophil recovery is particu-
larly significant because neutrophils play an
important role in the host defence against Muco-
rales.11 Of our 8 treated patients, 5 had progres-
sion of hematologic malignancy and none of
these responded to therapy; the 3 surviving
patients, on the other hand, were in complete
remission from leukemia.
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Table 1. Year of diagnosis, clinical characteristics, localizations, diagnostic procedures,  therapy and outcome of patients with
mucormycosis.
Patient Diagn. Age/sex Underlying disease Steroids Hematologic Localizations Diagnostic Antifungal Outcome
(year) therapy procedures therapy
1 1987 73/M AML (resistant) No No Lungs, esophagus Autopsy No died
2 1988 60/M AML No Chemotherapy Lungs Autopsy No died
3 1989 63/M AML  (resistant) No Chemotherapy Lungs, brain, kydney, heart Autopsy Ampho B 1 mg/kg died
4 1994 75/M AML No No Lung Autopsy No died
5 1994 64/F AML (resistant) yes HD ARA-C Lung, heart Autopsy Ampho B 1 mg/kg died
6 1995 75/M AML No No Lung Autopsy No died
7 1995 49/M NHL (resistant) yes Chemotherapy Lung, liver, kydney Autopsy No died
8 1996 20/M NHL No HD ARA-C Lung, heart, liver, brain, kydney Autopsy Ambisome 3 mg/kg died
9 1997 63/M AML No Chemotherapy Lung Lobectomy Ampho B  1 mg/kg survived
10 1997 61/M AML No Chemotherapy Lung, liver, brain Autopsy Ampho B 1 mg/Kg died
11 1998 37/F AML  (resistant) No HD ARA-C Lung, liver, heart, kydney Autopsy Ampho B 1 mg/kg died
12 1999 26/M AML No HD ARA-C Lungs, brain Biopsy Ambisome 5 mg/kg survived
13 1999 57/F AML No HD ARA-C Lungs Biopsy Ampho B 1 mg/Kg survived
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Despite the risk of renal toxicity, amphotericin
B at a high dose (1-1.5 mg/kg/day) remains the
gold standard antifungal agent against mucormy-
cosis and early aggressive pre-emptive therapy to
prevent cerebral involvement provides the best
chance of a favorable outcome. Mucormycosis
was almost invariably fatal if untreated.
Recently, the use of lipid formulations of
amphotericin B have been reported to be effec-
tive in the treatment of mucormycosis.7,12-14 In
our patient with cerebellar localization, Ambi-
some® (5 mg/kg daily) was able to limit cerebral
expansion of infection until neutrophils and
platelets recovered and it was possible to drain
the cerebellar abscess; it may be possible that
the lipid vehicle of amphotericin permits a high-
er concentration of drug in the cerebral tissue.
Surgery is curative in some cases of filamen-
tous mycoses and is an important component of
treatment in others;3 it is the treatment of choice
in patients with localized disease of sinuses or
the lung.8 In our experience surgery was an emer-
gency procedure in 2 patients, because of the
appearance of hemoptysis in one and of cerebral
hypertension in the other.
In conclusion, a high index of suspicion and
careful clinical and radiologic examinations are
the key to early identification of probably infect-
ed patients. In most severely ill neutropenic
patients, only aggressive antifungal therapy
together with immune reconstitution appears to
improve the outcome of patients with mucormy-
cosis. Moreover culture results and/or histologic
diagnosis are indispensable for programming sec-
ondary prophylaxis with amphotericin B or lipo-
somal amphotericin, because Mucor is not respon-
sive to azoles.15 The outcome, however, remains
critical: in hematologic neutropenic patients
mucormycosis is frequently characterized by dis-
seminated disease and a rapidly fatal course.
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Mucormycosis in hematologic malignancies
Potential implications for clinical practice
♦ Mucor infections can complicate hematologic
infections. They may be misdiagnosed as
Aspergillus infections. Invasive diagnosis, early
aggressive treatment with amphotericin B and
treatment of the underlying hematologic disease
seem to be particularly important for a favor-
able outcome of this frequently fatal infection.
